Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GRFS 
Grifols SA ADR (GRFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GRFS (1-star) is a SELL. SELL since 1 days. Profits (27.85%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.19
1 Year Target Price $12.19
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.11% | Avg. Invested days 41 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.56B USD | Price to earnings Ratio 19.35 | 1Y Target Price 12.19 |
Price to earnings Ratio 19.35 | 1Y Target Price 12.19 | ||
Volume (30-day avg) 2 | Beta 0.97 | 52 Weeks Range 6.09 - 10.96 | Updated Date 08/29/2025 |
52 Weeks Range 6.09 - 10.96 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 1.78% | Basic EPS (TTM) 0.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4% | Operating Margin (TTM) 18.48% |
Management Effectiveness
Return on Assets (TTM) 4.43% | Return on Equity (TTM) 4.99% |
Valuation
Trailing PE 19.35 | Forward PE 12.79 | Enterprise Value 18158018085 | Price to Sales(TTM) 1.15 |
Enterprise Value 18158018085 | Price to Sales(TTM) 1.15 | ||
Enterprise Value to Revenue 2.1 | Enterprise Value to EBITDA 9.64 | Shares Outstanding 258224000 | Shares Floating 561119682 |
Shares Outstanding 258224000 | Shares Floating 561119682 | ||
Percent Insiders - | Percent Institutions 57.65 |
Upturn AI SWOT
Grifols SA ADR
Company Overview
History and Background
Grifols SA was founded in Barcelona, Spain, in 1909. Initially a small laboratory, it evolved into a global leader in plasma-derived therapies, expanding through research, acquisitions, and international expansion.
Core Business Areas
- Bioscience: Production of plasma-derived therapies used to treat a variety of rare, chronic, and life-threatening conditions. These include immunoglobulins, albumin, alpha-1 antitrypsin, and clotting factors.
- Diagnostic: Development and manufacturing of in-vitro diagnostic products and solutions used for transfusion medicine, histocompatibility testing, and clinical diagnostics.
- Hospital: Provision of hospital pharmacy solutions, including IV solutions, nutrition products, and related equipment.
- Bio Supplies: Biological materials for research and manufacturing of biological medicines
Leadership and Structure
The leadership includes the CEO (currently Steven F. Mayer, appointed 2024). The organizational structure is hierarchical, with regional and functional divisions reporting to central management.
Top Products and Market Share
Key Offerings
- Albumin: Albumin is a plasma protein used to treat hypovolemia and other conditions. Grifols is a major producer. Competitors: CSL Behring, Takeda.
- Market Share: Grifols is estimated to hold a significant portion of the global market share of albumin.
- Immunoglobulins (IVIG): IVIG products are used to treat immune deficiencies and autoimmune disorders. Major revenue driver for Grifols. Competitors: CSL Behring, Takeda, Octapharma.
- Market Share: Grifols is a leading producer of IVIG products.
- Alpha-1 Antitrypsin (AAT): AAT is used to treat alpha-1 antitrypsin deficiency. Competitors: CSL Behring, Takeda.
- Market Share: Grifols has a significant market share within the AAT market.
Market Dynamics
Industry Overview
The plasma-derived therapies market is growing due to increasing demand for immunoglobulin therapies, rising prevalence of chronic diseases, and technological advancements. Regulations by health agencies, such as the FDA, play a crucial role.
Positioning
Grifols is a vertically integrated player, from plasma collection to manufacturing. Competitive advantages include a large plasma collection network and established market presence.
Total Addressable Market (TAM)
The global plasma fractionation market is projected to reach over $45 billion by 2028. Grifols is well-positioned to capture a significant share of this expanding market.
Upturn SWOT Analysis
Strengths
- Extensive plasma collection network
- Diversified product portfolio
- Strong R&D capabilities
- Global presence
Weaknesses
- High debt levels
- Plasma collection costs
- Regulatory scrutiny
- Competition from larger players
Opportunities
- Expanding plasma collection capacity
- Developing new plasma-derived therapies
- Geographic expansion into emerging markets
- Strategic acquisitions
Threats
- Increased competition
- Plasma supply disruptions
- Pricing pressures
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- CSL.AX
- TAK
- OCGN
Competitive Landscape
Grifols faces intense competition. Its strength is its plasma collection network; disadvantages include higher debt levels. CSL.AX (CSL Behring) is a key competitor with greater resources.
Major Acquisitions
Biotest US Plasma Centers
- Year: 2022
- Acquisition Price (USD millions): 286
- Strategic Rationale: Expanded plasma collection network.
Growth Trajectory and Initiatives
Historical Growth: Grifols has historically grown through acquisitions and expansion of its plasma-derived therapies. Recent growth rates should be checked.
Future Projections: Analyst estimates project continued growth in line with the plasma-derived therapies market. Specific projections would be available through financial data providers.
Recent Initiatives: Recent initiatives include expanding plasma collection centers and developing new therapies.
Summary
Grifols is a leading player in the plasma-derived therapies market, driven by its strong plasma collection network and diversified product portfolio. However, the company faces challenges due to high debt and intense competition. Expanding plasma collection and developing new therapies are key to future growth. Maintaining a focus on innovation and careful financial management will be crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Industry analysis reports
- Financial news sources
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Grifols SA ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2006-05-17 | CEO & Director Mr. Jose Ignacio Abia Buenache | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 23833 | Website https://www.grifols.com |
Full time employees 23833 | Website https://www.grifols.com | ||
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.